@article{HohenauerBerkingSchmidtetal.2013, author = {Hohenauer, Tobias and Berking, Carola and Schmidt, Andreas and Haferkamp, Sebastian and Senft, Daniela and Kammerbauer, Claudia and Fraschka, Sabine and Graf, Saskia Anna and Irmler, Martin and Beckers, Johannes and Flaig, Michael and Aigner, Achim and H{\"o}bel, Sabrina and Hoffmann, Franziska and Hermeking, Heiko and Rothenfusser, Simon and Endres, Stefan and Ruzicka, Thomas and Besch, Robert}, title = {The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival}, series = {EMBO Molecular Medicine}, volume = {5}, journal = {EMBO Molecular Medicine}, issn = {1757-4676}, doi = {10.1002/emmm.201201862}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-122193}, pages = {919-934}, year = {2013}, abstract = {Pigment cells and neuronal cells both are derived from the neural crest. Here, we describe the Pit-Oct-Unc (POU) domain transcription factor Brn3a, normally involved in neuronal development, to be frequently expressed in melanoma, but not in melanocytes and nevi. RNAi-mediated silencing of Brn3a strongly reduced the viability of melanoma cell lines and decreased tumour growth in vivo. In melanoma cell lines, inhibition of Brn3a caused DNA double-strand breaks as evidenced by Mre11/Rad50-containing nuclear foci. Activated DNA damage signalling caused stabilization of the tumour suppressor p53, which resulted in cell cycle arrest and apoptosis. When Brn3a was ectopically expressed in primary melanocytes and fibroblasts, anchorage-independent growth was increased. In tumourigenic melanocytes and fibroblasts, Brn3a accelerated tumour growth in vivo. Furthermore, Brn3a cooperated with proliferation pathways such as oncogenic BRAF, by reducing oncogene-induced senescence in non-malignant melanocytes. Together, these results identify Brn3a as a new factor in melanoma that is essential for melanoma cell survival and that promotes melanocytic transformation and tumourigenesis.}, language = {en} } @article{GewiesGorkaBergmannetal.2014, author = {Gewies, Andreas and Gorka, Oliver and Bergmann, Hanna and Pechloff, Konstanze and Petermann, Franziska and Jeltsch, Katharina M. and Rudelius, Martina and Kriegsmann, Mark and Weichert, Wilko and Horsch, Marion and Beckers, Johannes and Wurst, Wolfgang and Heikenwalder, Mathias and Korn, Thomas and Heissmeyer, Vigo and Ruland, Juergen}, title = {Uncoupling Malt1 Threshold Function from Paracaspase Activity Results in Destructive Autoimmune Inflammation}, series = {Cell Reports}, volume = {9}, journal = {Cell Reports}, number = {4}, doi = {10.1016/j.celrep.2014.10.044}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-114627}, pages = {1292-1305}, year = {2014}, abstract = {The paracaspase Malt1 is a central regulator of antigen receptor signaling that is frequently mutated in human lymphoma. As a scaffold, it assembles protein complexes for NF-kappa B activation, and its proteolytic domain cleaves negative NF-kappa B regulators for signal enforcement. Still, the physiological functions of Malt1-protease are unknown. We demonstrate that targeted Malt1-paracaspase inactivation induces a lethal inflammatory syndrome with lymphocyte-dependent neurodegeneration in vivo. Paracaspase activity is essential for regulatory T cell (Treg) and innate-like B cell development, but it is largely dispensable for overcoming Malt1-dependent thresholds for lymphocyte activation. In addition to NF-kappa B inhibitors, Malt1 cleaves an entire set of mRNA stability regulators, including Roquin-1, Roquin-2, and Regnase-1, and paracaspase inactivation results in excessive interferon gamma (IFN gamma) production by effector lymphocytes that drive pathology. Together, our results reveal distinct threshold and modulatory functions of Malt1 that differentially control lymphocyte differentiation and activation pathways and demonstrate that selective paracaspase blockage skews systemic immunity toward destructive autoinflammation.}, language = {en} }